Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

766
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
766
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

4.4K
Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
4.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

EBV and immunodeficiency: the odd couple drawn to the brain.

Blood·2026
Same author

Application of Hi-C sequencing to detect oncogene rearrangements for diagnosis and treatment of large B-cell lymphoma.

Blood advances·2026
Same author

Beyond biomarkers: tissue still matters.

The Lancet. Haematology·2026
Same author

SOHO State of the Art Updates and Next Questions | Management of Primary Central Nervous System Lymphoma.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Addition of autologous stem-cell transplantation to an ibrutinib-containing first-line treatment in patients aged 18-65 years with mantle cell lymphoma (TRIANGLE): 4·5-year follow-up of a three-arm, randomised, open-label, phase 3 superiority trial of the European MCL Network.

Lancet (London, England)·2026
Same author

Hepatitis C virus and hepatitis B virus in indolent lymphomas: Prospective data from the international observational NF10 study.

British journal of haematology·2026
Same journal

Somatostatin receptor PET response assessment framework for patients with neuroendocrine tumours (V1.0): a modified Delphi consensus from the European Neuroendocrine Tumor Society (endorsed by EANM and NANETS).

The Lancet. Oncology·2026
Same journal

Differential impact of proton pump inhibitors and antibiotics on immunotherapy efficacy after chemoradiotherapy in locally advanced non-small-cell lung cancer: a post-hoc analysis of the PACIFIC trial.

The Lancet. Oncology·2026
Same journal

Co-medications and gut microbiome in NSCLC immunotherapy.

The Lancet. Oncology·2026
Same journal

Carcinogenicity of butyl benzyl phthalate, dibutyl phthalate, and diisononyl phthalate.

The Lancet. Oncology·2026
Same journal

New report sheds light on cancer disparities in the USA.

The Lancet. Oncology·2026
Same journal

Review highlights gaps in South Africa's cancer care.

The Lancet. Oncology·2026
See all related articles

Related Experiment Video

Updated: Aug 30, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.5K

CNS prophylaxis for diffuse large B-cell lymphoma.

Toby A Eyre1, Kerry J Savage2, Chan Y Cheah3

  • 1Department of Haematology, Churchill Hospital, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

The Lancet. Oncology
|September 2, 2022
PubMed
Summary
This summary is machine-generated.

Central nervous system (CNS) relapse is a rare but severe complication of diffuse large B-cell lymphoma. This review examines CNS prophylaxis strategies, their risks, and future directions for preventing lymphoma spread to the brain.

More Related Videos

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K

Related Experiment Videos

Last Updated: Aug 30, 2025

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

10.5K
Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts
11:15

Stereotactic Adoptive Transfer of Cytotoxic Immune Cells in Murine Models of Orthotopic Human Glioblastoma Multiforme Xenografts

Published on: September 1, 2018

8.0K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.4K

Area of Science:

  • Oncology
  • Neurology
  • Hematology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) can spread to the central nervous system (CNS), a devastating complication.
  • CNS relapse is uncommon but significantly impacts patient outcomes.
  • Risk factors for CNS involvement in DLBCL are becoming better understood.

Purpose of the Study:

  • To review historical and current developments in CNS prophylaxis for DLBCL.
  • To discuss the rationale for and against current prophylactic strategies.
  • To outline evidence on the optimal timing of prophylactic interventions.

Main Methods:

  • Literature review of clinical and biological features associated with CNS relapse risk.
  • Analysis of historical and contemporary CNS prophylaxis strategies (intrathecal chemotherapy, high-dose antimetabolites).
  • Discussion of evidence regarding the timing and efficacy of prophylactic measures.

Main Results:

  • Clinical and biological risk factors for CNS relapse in DLBCL are increasingly defined.
  • Various CNS prophylaxis strategies exist, with ongoing debate regarding their standard use.
  • Evidence for the optimal timing of prophylactic interventions is being established.

Conclusions:

  • CNS prophylaxis in DLBCL remains a complex and evolving area.
  • A nuanced approach considering individual patient risk is crucial.
  • Future developments may refine or personalize CNS prophylaxis strategies.